Blood cancer is one of the more treatable cancer categories, though outcomes vary widely depending on the specific type. Five-year survival rates range from about 63% for myeloma to nearly 90% for Hodgkin lymphoma, and certain subtypes have cure rates well above 90%. The answer to “how treatable” depends heavily on which blood cancer you’re talking about, the stage at diagnosis, your age, and increasingly, the genetic profile of the cancer itself.
Survival Rates by Type
Blood cancers fall into three broad families: leukemia, lymphoma, and myeloma. Each behaves differently and responds to treatment differently. Based on the most recent national data (SEER, 2016-2022), here’s how they compare:
- Hodgkin lymphoma: 89.3% five-year survival. Even at stage IV, survival sits around 83%.
- Non-Hodgkin lymphoma: 74.2% five-year survival, though this is an average across dozens of subtypes that range from highly curable to very difficult to treat.
- Leukemia: 67.8% overall, but individual subtypes tell a much more useful story (more on that below).
- Myeloma: 63.7% five-year survival. When caught early and localized, that number climbs to about 82%.
These numbers represent relative survival, meaning they compare people with the cancer to people of the same age without it. They reflect real-world outcomes across all patients, all stages, and all treatment approaches.
Leukemia: Four Diseases Under One Name
The word “leukemia” covers at least four distinct diseases, and their treatability is not remotely the same. Chronic lymphocytic leukemia (CLL), the most common adult leukemia, has a five-year survival rate above 90%. Many people with CLL live for decades, and some never need treatment at all. It’s often managed as a chronic condition rather than something requiring aggressive intervention.
Chronic myeloid leukemia (CML) was once a death sentence. The discovery that CML is driven by a specific genetic rearrangement (called the Philadelphia chromosome) led to drugs that block the protein this mutation produces. These medications transformed CML into a disease most patients can control with a daily pill, often for the rest of their lives.
Acute leukemias are more aggressive. Acute myeloid leukemia (AML) in adults has a tougher prognosis overall, but outcomes depend enormously on the specific genetic mutations involved. Some mutations make the cancer much more responsive to targeted drugs, while others signal a more resistant disease. Stem cell transplant dramatically improves the picture for many AML patients, pushing five-year survival to around 65% compared to roughly 24% without transplant.
Childhood leukemia tells the most encouraging story of all. Pediatric leukemia, mostly acute lymphoblastic leukemia (ALL), has an overall five-year survival of about 87%. Some subtypes in children exceed 95% survival. This is one of the great success stories of modern oncology.
Lymphoma: Often Curable
Hodgkin lymphoma is among the most curable cancers in medicine. Even when it has spread to both sides of the body, five-year survival remains above 80%. For earlier stages, it exceeds 92%. Most patients are treated with chemotherapy, sometimes combined with radiation, and a majority achieve long-term remission that is effectively a cure.
Non-Hodgkin lymphoma is harder to generalize because it includes more than 60 subtypes. Some aggressive forms, like diffuse large B-cell lymphoma (the most common type), respond well to treatment and can be cured in a significant number of cases. Slower-growing forms may not be curable in the traditional sense but can often be managed for many years, cycling through periods of treatment and remission.
Myeloma: Not Curable, but Increasingly Manageable
Multiple myeloma remains one of the harder blood cancers to treat, and it’s generally considered incurable with current therapies. But “incurable” doesn’t mean “untreatable.” The landscape has changed dramatically. Five-year survival has climbed to nearly 64% overall and above 80% for localized disease. Patients today often go through multiple rounds of treatment over many years, with periods of remission between them. New drug combinations have steadily pushed survival times longer, and many patients live 10 years or more after diagnosis.
Certain genetic features in myeloma cells signal higher risk, including specific chromosomal rearrangements and deletions. Patients with these markers typically face shorter remissions and may need more aggressive treatment strategies, though even high-risk myeloma is responding better to newer therapies than it did a decade ago.
How Blood Cancer Is Treated
Treatment for blood cancers generally falls into three core approaches, often used in combination. Chemotherapy kills rapidly dividing cancer cells and remains the backbone of treatment for many blood cancers. Targeted therapy exploits specific genetic vulnerabilities in the cancer cells, blocking the proteins that drive their growth. Immunotherapy enhances your own immune system’s ability to recognize and destroy cancer cells.
Which combination you receive depends on the exact diagnosis. Genetic testing of the cancer cells has become standard practice because the mutations present in your specific cancer often determine which treatments will work best. A leukemia driven by one mutation may respond beautifully to a targeted pill, while the same type of leukemia with a different mutation may require intensive chemotherapy and a transplant.
Stem Cell Transplants
Stem cell transplant (sometimes called bone marrow transplant) is used when the goal is to wipe out the diseased bone marrow entirely and replace it with healthy cells. This can involve your own stem cells, collected and stored before high-dose chemotherapy, or donor cells from a matched individual. It’s an intensive process with significant risks, but for certain leukemias and lymphomas, it offers the best chance at long-term remission or cure.
CAR-T Cell Therapy
One of the most significant advances in blood cancer treatment is CAR-T cell therapy, which involves removing a patient’s immune cells, engineering them in a lab to recognize cancer, and infusing them back. In adults with B-cell acute lymphoblastic leukemia, this approach has produced remission rates exceeding 70%, even in patients whose cancer had stopped responding to other treatments. When patients relapse after an initial round, switching to a different version of CAR-T therapy can still achieve complete remission in roughly 78% of cases. CAR-T is now approved for several types of lymphoma and leukemia and is being tested in myeloma.
What Determines Your Individual Outlook
Averages only tell part of the story. Several factors shift the odds significantly for any individual patient:
- Specific subtype: This matters more than almost anything else. The difference between a 90% survival rate and a 30% survival rate often comes down to exactly which blood cancer you have.
- Genetic profile of the cancer: Mutations within the cancer cells can make them more or less responsive to available treatments. Some mutations are specifically targetable with precision drugs, which dramatically improves outcomes.
- Age: Younger patients generally tolerate more intensive treatments and tend to have better outcomes. Childhood leukemia survival rates are roughly 20 percentage points higher than the adult average.
- Stage at diagnosis: For lymphomas and myeloma, earlier detection generally means better outcomes. Localized myeloma has an 82% five-year survival compared to 63% when it’s widespread.
- Response to initial treatment: How quickly and completely the cancer responds to first-line therapy is one of the strongest predictors of long-term outcome. Doctors now measure this with extraordinary precision, detecting as few as one cancer cell among a thousand normal cells to determine whether residual disease remains.
What Remission Actually Means
You’ll hear the word “remission” frequently in blood cancer treatment, and it’s worth understanding what it means in practice. Complete remission means no detectable cancer on standard tests. It does not always mean cured. Some blood cancers, particularly myeloma and certain leukemias, can return months or years after remission.
Increasingly, doctors look beyond standard remission to something called MRD negativity, meaning no cancer is detectable even with the most sensitive laboratory techniques. Achieving this deeper level of response is associated with longer remissions and better long-term survival. It’s becoming a key goal of treatment and a useful benchmark for predicting how well someone will do over time.
For cancers like Hodgkin lymphoma and childhood ALL, remission after initial treatment very often does mean cure. For others like CML, “remission” means the disease is controlled, potentially indefinitely, as long as treatment continues. And for myeloma, remission is typically temporary but increasingly long-lasting with modern therapies. The word means different things depending on the disease, and understanding which version applies to your diagnosis is one of the most important conversations to have with your care team.